Overview

The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Non-alcoholic Fatty Liver Disease

Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
0
Participant gender:
All
Summary
The role of Helicobacter pylori(HP)in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) is controversial.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Tehran University of Medical Sciences
Treatments:
Amoxicillin
Azithromycin
Bismuth
Bismuth tripotassium dicitrate
Omeprazole
Criteria
Inclusion Criteria:

- dyspeptic patients with positive antibody to H.pylori and

- persistent elevated aminotransferase levels with the evidence of fatty liver in
ultrasonography, who were referred to a gastroenterology clinic.

Exclusion Criteria:

- alcohol use (more than 20 gram per day in men and 10 gram per day in women per day),

- heart disease (ischemic or congestive),

- hepatic disease (viral hepatitis, autoimmune hepatitis, wilson disease,
hemochromatosis, liver mass lesion),

- renal disease (serum creatinine concentration of > 1.5 mg/dl),

- any severe systemic co-morbidities, neoplasm,

- using any hepatotoxic medication during the past 3 months,

- previous history of peptic ulcer,

- previous history of H.pylori eradication,

- existence of alarm signs (weight loss, dysphagia, anemia, vomiting, positive family
history of gastrointestinal cancers), and

- pregnant or lactating women.